Antineoplastics (PARP inhibitors)
- Exploit impaired tumor DNA repair
- BRCA/HRD tumors are major targets
- Olaparib is the broadest familiar example
- Ovarian/breast/prostate uses vary by drug
- Anemia, fatigue + nausea are common
- Rare MDS/AML is a serious long-term risk
- Biomarker + prior therapy determine use
Class at a glance
- Exploit impaired tumor DNA repair
Practical pearls
- BRCA/HRD tumors are major targets
- Olaparib is the broadest familiar example
Clinical role
- Ovarian/breast/prostate uses vary by drug
- Anemia, fatigue + nausea are common
- Biomarker + prior therapy determine use
Safety / monitoring
- Rare MDS/AML is a serious long-term risk
Self-check
- What common adverse effects occur with PARP inhibitors?
Anemia, fatigue, and nausea.
- What rare serious long-term toxicity can occur?
MDS/AML.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
